DXCM

DEXCOM INC

Healthcare • USA

Apr 05 • 04:00PM ET
85.48
-0.19 (-0.22%)
Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devic ... read more

Full Time Employees 9,500
Phone 858 200 0200
Website https://www.dexcom.com
CEO Mr. Kevin Ronald Sayer
IPO Date 2005-04-14
Sector Healthcare
Industry Medical - Devices
Address 6340 Sequence Drive, San Diego, CA 92121
Balance Sheet
Total Cash $904,900,000
Total Debt $2,525,600,000
Current Ratio 1.50
Quick Ratio 1.27
Profitability
Gross Margin 59.43%
Net Margin 12.90%
ROE 23.61%
ROA 7.93%
ROIC 9.67%
Balance Sheet
Total Cash $904,900,000
Total Debt $2,525,600,000
Current Ratio 1.50
Quick Ratio 1.27
Profitability
Gross Margin 59.43%
Net Margin 12.90%
ROE 23.61%
ROA 7.93%
ROIC 9.67%
Name DEXCOM INC Sector Healthcare Currency USD Relative Volume 1.64 Market Cap 23379
Current Ratio 1.47 Dividend / Share 0.0 EPS 1.42 Revenue 4033000000 P/S 5.8
P/E 40.6 Beta 0.56 Income 576200000 Volume 6550793 Average Volume 3994357
Distance to 200DMA -25.48% 200 DMA 80.29 50 DMA 80.14 ROA 8.8 ROE 26.3
Distance to 50DMA -25.34% Return 1Y -56.8% Return YTD -23.07% Forward PE Qtly Growth YOY
Debt/Eq 2.08 P/B 11.1 Dividend Yield 0.0% Net Margin 14.29% Payout Ratio 0.0
Performance
52 Week Range 0.0%
Distance to 200DMA 0.0%
Day Change Percent $0.00

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $621,200,000
Total Debt $2,533,000,000
Current Ratio 2.46%
Quick Ratio 0.94%
Profitability
Gross Margin 59.43%
Net Margin 12.90%
ROE 23.61%
ROA 7.93%
ROIC 9.67%
Valuation
Price to Earnings 62.46
Price to Book 14.75
Price to Sales 8.06
Price to Free Cash Flow 58.12
Dividends
Payout Ratio 0.00%
Dividend Yield 0.00%
Dividend Amount $0.00
Performance
52 Week Range 0.0%
Distance to 200DMA 0.0%
Day Change Percent $0.00
Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devic ... read more

Full Time Employees 9,500
Phone 858 200 0200
Website https://www.dexcom.com
CEO Mr. Kevin Ronald Sayer
IPO Date 2005-04-14
Sector Healthcare
Address 6340 Sequence Drive, San Diego, CA 92121
Histogram - Daily

Balance Sheet
Total Cash $621,200,000
Total Debt $2,533,000,000
Current Ratio 2.46%
Quick Ratio 0.94%
Profitability
Gross Margin 0.6170%
Net Margin 0.1720%
ROE 0.31%
ROA 0.10%
Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devic ... read more

Full Time Employees 9,500
Phone 858 200 0200
Website https://www.dexcom.com
CEO Mr. Kevin Ronald Sayer
IPO Date 2005-04-14
Sector Healthcare
Address 6340 Sequence Drive, San Diego, CA 92121
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil

Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.

2025-05-15 09:11:13 - zacks.com
Top Health & Fitness Stocks to Buy for the Wellness Boom
Top Health & Fitness Stocks to Buy for the Wellness Boom

The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.

2025-05-14 10:01:25 - zacks.com
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and C

SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO.

2025-05-13 08:30:00 - businesswire.com
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2025-05-12 13:05:40 - zacks.com
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns

Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.

2025-05-12 10:10:52 - zacks.com
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, gr

2025-05-09 11:00:41 - seekingalpha.com
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case

DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that unders

2025-05-08 07:31:51 - marketbeat.com
5 Best Stocks of the S&P 500 ETF in the Past Month
5 Best Stocks of the S&P 500 ETF in the Past Month

The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.

2025-05-05 11:50:39 - zacks.com
DexCom: Growth Is Reaccelerating But Don't Ignore The Risks
DexCom: Growth Is Reaccelerating But Don't Ignore The Risks

I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establish

2025-05-05 04:34:04 - seekingalpha.com
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins

DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new marke

2025-05-02 14:25:33 - zacks.com
Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism
Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism

Nasdaq jumps as Dexcom, Palantir, and ON Semi soar. Jobs report beats forecasts, easing inflation fears and driving US stock market optimism.

2025-05-02 13:43:14 - fxempire.com
Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.
Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.

Dexcom, the maker of glucose monitors for patients with diabetes, reports a strong first quarter.

2025-05-02 11:53:00 - barrons.com
2 Growth Stocks to Buy and Hold for a Decade
2 Growth Stocks to Buy and Hold for a Decade

Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock mar

2025-05-02 04:16:00 - fool.com
Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e

2025-05-01 18:30:39 - zacks.com
DexCom (DXCM) Q1 Earnings Miss Estimates
DexCom (DXCM) Q1 Earnings Miss Estimates

DexCom (DXCM) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.32 per share a year ago.

2025-05-01 18:20:45 - zacks.com
Dexcom beats quarterly sales estimates, reiterates annual forecast
Dexcom beats quarterly sales estimates, reiterates annual forecast

Medical device maker Dexcom beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

2025-05-01 16:54:11 - reuters.com